Drug
Pevonedistat clinical trials
Also written MLN4924 and TAK-924.
- studies test it
- 34
- open now
- 1
- in phase 3
- 3
- first study started
- 2008
Keep track of what changes. Save the pevonedistat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2018 (7)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 7 |
| 2019 | 7 |
| 2020 | 4 |
| 2021 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 22
- Phase 2
- 14
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 22
Millennium Pharmaceuticals, Inc. (8) · National Cancer Institute (NCI) (6) · Takeda (4) · M.D. Anderson Cancer Center (2) · City of Hope Medical Center (2) · PETHEMA Foundation (1) · University of Southern California (1) · Vanderbilt-Ingram Cancer Center (1)
Often tested with
Tested in the same studies.
Azacitidine (8) · Cytarabine (4) · Venetoclax (3) · Decitabine (3) · Carboplatin (1) · Paclitaxel (1) · Idarubicin (1) · Ibrutinib (1)
Studies
Open first, then newest update. How each study uses pevonedistat is read from its arms, and is right about nine times in ten.
Testing it · 34
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as Pevonedistat (BAML-16-001-S9)
- A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive ChemotherapyCompletedPhase 2TakedaNCT04266795Written as Pevonedistat
- Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With ImmunotherapyActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03965689Written as Pevonedistat
- Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT03862157Written as Pevonedistat
- Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard ChemotherapyActive, not recruitingPhase 3PETHEMA FoundationNCT04090736Written as Pevonedistat
- Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingPhase 1/2University of Southern CaliforniaNCT03330821Written as Pevonedistat
- Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaActive, not recruitingPhase 1City of Hope Medical CenterNCT03479268Written as Pevonedistat
- Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid LeukemiaCompletedPhase 1City of Hope Medical CenterNCT03009240Written as Pevonedistat
- Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedPhase 1National Cancer Institute (NCI)NCT03772925Written as Pevonedistat
- Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)CompletedPhase 3TakedaNCT03268954Written as Pevonedistat
- Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to TreatmentCompletedPhase 1National Cancer Institute (NCI)NCT03770260Written as Pevonedistat
- Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedPhase 1National Cancer Institute (NCI)NCT03813147Written as Pevonedistat
- Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase InhibitorsCompletedPhase 2Vanderbilt-Ingram Cancer CenterNCT03238248Written as Pevonedistat Infusion
- Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedPhase 1Children's Oncology GroupNCT03323034Written as Pevonedistat
- A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver ProblemsCompletedPhase 1TakedaNCT03814005Written as Pevonedistat
- Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaTerminatedPhase 1Medical College of WisconsinNCT04172844Written as Pevonedistat
- A Study of Pevonedistat in Adult East Asian ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02782468Written as Pevonedistat 25 mg/m^2
- Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung CancerTerminatedPhase 2University of Michigan Rogel Cancer CenterNCT03228186Written as Pevonedistat
- Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and PevonedistatCompletedPhase 2University of LeipzigNCT04712942Written as Pevonedistat
- Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnPhase 2National Cancer Institute (NCI)NCT03745352Written as Pevonedistat
See all 34 studies that test pevonedistat →
Given in every arm · 6 — pevonedistat is usual care beside what is tested
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the LiverActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04175912Written as Pevonedistat
- Pevonedistat Alone and in Combination With Chemotherapy in Patients With MesotheliomaTerminatedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03319537Written as pevonedistat
- A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid TumorsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03330106Written as Pevonedistat
- A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid TumorsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03486314Written as Pevonedistat
- Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid TumorsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT01862328Written as MLN4924
- Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid TumorsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02122770Written as MLN4924
Codes
What other systems call pevonedistat · ClinicalTrials.gg INT005416
- MeSH (NLM) C539933pevonedistatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S3AZD8D215PEVONEDISTATConfirmed FDA, NLM, Wikidata
- Wikidata Q25100575PevonedistatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77906PevonedistatOne source FDA
- DrugBank DB11759One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C539933 | pevonedistat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S3AZD8D215 | PEVONEDISTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q25100575 | Pevonedistat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77906 | Pevonedistat | One source FDA |
| DrugBank | DB11759 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.